Gottlieb slams PBMs

In a series of tweets on Thursday, FDA Commissioner Scott Gottlieb slammed agreements between brand-name drug manufacturers and PBMs that he said diminished generic competition.

Earlier this month, Gottlieb criticized anticompetitive consolidations of PBMs and other industry players in a speech to the trade group America’s Health Insurance Plans (AHIP) (see BioCentury, March 23)...